The activation of ERK1/2 has been demonstrated to play a crucial role in the TGF-β dependent malignant transformation of pancreatic cancer [37]; this is because KRAS mutations and altered TGF-β signalling are frequent in pancreatic cancer [38]. This evidence concerns the gene KRAS and pancreatic neoplasm.